Jaguar Health, Inc. current report, 13 January 2021

Full document

Jaguar Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on January 13, 2021. The filing reports the entry into a Material Definitive Agreement regarding a registered public offering of common stock.

Key Financial Metrics and Transaction Details

  • Transaction Type: Registered public offering of common stock.
  • Shares Issued: 4,437,870 shares.
  • Offering Price: $3.38 per share.
  • Gross Proceeds: Approximately $15 million.
  • Placement Agent: Ladenburg Thalmann & Co. Inc.
  • Agent Fees: 8% placement fee, 1% management fee, plus $75,000 expense reimbursement.
  • Expected Closing Date: January 15, 2021.

The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics as this is a transactional report rather than a periodic financial statement.

Material Changes

The primary material change is the execution of a Securities Purchase Agreement to raise capital. The offering price represents a premium to the market price as defined by Nasdaq Listing Rule 5635(d). No prior comparable period financial data is presented in this document.

Outlook, Risks, and Unusual Items

The Company expects to file a prospectus supplement on or about January 14, 2021. The closing of the offering is subject to the satisfaction of customary closing conditions. The filing includes standard representations, warranties, and indemnification provisions customary for such transactions. No specific forward-looking guidance or risk factors beyond standard transaction contingencies are detailed in this excerpt.

Investor Verification Checklist

  • Verify the final closing date of the offering (expected January 15, 2021).
  • Confirm the net proceeds after deducting the 9% total agent fees and $75,000 in expenses.
  • Review the attached Press Release (Exhibit 99.1) for the intended use of proceeds.
  • Check the prospectus supplement (to be filed) for updated risk factors.
  • Monitor the impact of the 4.4 million new shares on existing shareholder dilution.